Antidiabetic Properties of Rose Hip | NCT01316016

Studies
Antidiabetic Properties of Rose Hip

NCT01316016

Sponsor

Lund University

Status

Completed

Last Update Posted

Mar 16, 2011Estimated

Enrollment

31Actual

Phase

Not Applicable

Conditions

Obesity

Interventions

Rose hip

Countries

Sweden

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Feb 2011

Overall Recruitment Status or Expanded Access Status

Completed

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Apr 2009

Primary Completion Date

Feb 2010Actual

Completion Date

Jan 2011Actual

First Submitted Date

Mar 15, 2011

First Submission Date that Met QC Criteria

Mar 15, 2011

First Posted Date

Mar 16, 2011Estimated

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Mar 15, 2011

Last Update Posted Date

Mar 16, 2011Estimated

Oversight Module

Has Data Monitoring Committee (DMC)

Is FDA Regulated Drug

Not provided

Is FDA Regulated Device

Not provided

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

The purpose of this study is to determine whether daily intake of a drink containing rose hip powder reduces risk markers of type diabetes and cardiovascular disease.

Detailed Description

Not provided

Design Module

Study Type

Interventional

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Not Applicable

Interventional Study Design

Allocation

Biospecimen

No data available

No data is available for this block.

Enrollment

31Actual

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Rose hip	Experimental		Dietary Supplement: Rose hip

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Rose hip	Dietary Supplement	40 g of rose hip powder daily for 6 weeks.	Rose hip

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

BMI > 30
willingness to participate in the study
willingness to comply with the daily intake of drinks and the recommended energy intake during the course of the study

Exclusion Criteria:

diabetes
previous or ongoing insulin treatment
abnormal thyroid status
abnormal liver status
abnormal kidney status
known gastrointestinal disorder
pregnancy
suspected allergy to ingredients of the drinks

Accepts Healthy Volunteers

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

18 Years

Maximum Age

Not provided

Standard Ages

AdultOlder Adult

Study Population

Not provided

Sampling Method

Not provided

Contacts/Locations Module

Central Contacts

Not provided

Overall Officials

Name	Affiliation	Role
Per Katzman, MD/PhD	Lund University	Study Chair

Locations

Facility	Status	City	State	ZIP	Country	Contacts
Endocrinology Clinic, Lund University Hospital		Lund		SE-22185	Sweden

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
20959531	Background	Andersson U, Henriksson E, Strom K, Alenfall J, Goransson O, Holm C. Rose hip exerts antidiabetic effects via a mechanism involving downregulation of the hepatic lipogenic program. Am J Physiol Endocrinol Metab. 2011 Jan;300(1):E111-21. doi: 10.1152/ajpendo.00268.2010. Epub 2010 Oct 19.

ID	Term
D009765	Obesity
D018149	Glucose Intolerance

ID	Term
D050177	Overweight
D044343	Overnutrition
D009748	Nutrition Disorders
D009750	Nutritional and Metabolic Diseases